TABLE 2.
Detection of CT-Positive Lesions with Positron Emission Tomography
| Lesion site | 18F-FDG |
64Cu-DOTA-trastuzumab*
|
|
|---|---|---|---|
| Day 1 | Day 2 | ||
| All | 83 of 89 (93%) | 61 of 79 (77%)† | 54 of 61 (89%) |
| Bone | 35 of 38 (92%) | 33 of 36 (92%) | 19 of 20 (95%) |
| Lymph nodes | 30 of 31 (97%) | 20 of 31 (65%)‡,§ | 19 of 23 (88%) |
| Liver | 8 of 10 (80%) | 1 of 3 (33%) | 8 of 8 (100%) |
| Lung | 5 of 5 (100%) | 4 of 4 (100%) | 4 of 5 (80%) |
| Pleural effusion | 2 of 2 (100%) | 0 of 2 (0%) | 1 of 2 (50%) |
| Breast | 3 of 3 (100%) | 3 of 3 (100%) | 3 of 3 (100%) |
*
Combined data for 5 and 50 mg trastuzumab doses
†
P < 0.01 relative to 18F-FDG, all sites
‡
P < 0.01 relative to 18F-FDG, lymph nodes
§
P < 0.05 relative to 64Cu-DOTA-trastuzumab Day 1, bone